---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-205590"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:14:14.642279+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verrica FDA approval of YCANTH for molluscum and Q2 net loss $11M; cash runway to Q1 2025

## Summary
- FDA approved YCANTH (cantharidin) on July 21 for molluscum in patients 2+; launch by Sep 2023.
- Closed $125M debt facility with OrbiMed; drew $50M, up to $75M additional; cash extends into Q1 2025.
- Q2 GAAP net loss $11.0M ($0.24/share) vs $10.2M loss in prior year; non-GAAP loss $9.4M.
- Expanding Part 2 enrollment of VP-315 Phase 2 trial for basal cell carcinoma to accelerate development.
- Cash and equivalents $55.1M at June 30, 2023.

## SEC filing metadata
- accession: 0001193125-23-205590
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/0001193125-23-205590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/d512113d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-205590
- JSON: https://secwatch.observer/filing/0001193125-23-205590.json
- Plain text: https://secwatch.observer/filing/0001193125-23-205590.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported financial results for six months ended June 30, 2023.
  - Period: six months ended June 30, 2023
  - Result: reported results
  source text: Verrica Pharmaceuticals Inc. (the " Registrant ") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/0001193125-23-205590-index.htm
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported second quarter ended June 30, 2023 results: net income net loss on a GAAP basis was $11.0 million, or $0.24 per share, EPS net loss on a GAAP basis was $11.0 million, or $0.24 per share.
  - Period: second quarter ended June 30, 2023
  - Net income: net loss on a GAAP basis was $11.0 million, or $0.24 per share
  - EPS: net loss on a GAAP basis was $11.0 million, or $0.24 per share
  - Result: reported results
  source text: Verrica Pharmaceuticals Inc. (the " Registrant ") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/0001193125-23-205590-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.